Small-scale trial of vaccine’s efficacy shows it offers very little protection against mild to moderate infection
- Coronavirus – latest updates
- See all our coronavirus coverage
The Oxford/AstraZeneca vaccine offers as little as 10% protection against the Covid variant first seen in South Africa, researchers have suggested.
Scientists who conducted a small-scale trial of the vaccine’s efficacy said it showed very little protection against mild to moderate infection, though they expressed hope that – in theory – it would still offer significant protection against more serious infection.